TERT and neoplasm: We detected 44 HBV integration breakpoints in 23 (57.5%) of the primary tumor samples and 45 HBV integration breakpoints in 24 (60%) of the recurrent tumor samples, including recurrent HBV integration events in TERT, a well-known HCC driver gene (Supplementary Table 6).